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Abstract
BACKGROUND—Although state Medicaid programs cover cancer screening, Medicaid 
beneficiaries are less likely to be screened for cancer and are more likely to present with tumors of 
an advanced stage than are those with other insurance. The current study was performed to 
determine whether state Medicaid eligibility and reimbursement policies affect the receipt of 
breast, cervical, and colon cancer screening among Medicaid beneficiaries.
METHODS—Cross-sectional regression analyses of 2007 Medicaid data from 46 states and the 
District of Columbia were performed to examine associations between state-specific Medicaid 
reimbursement/eligibility policies and receipt of cancer screening. The study sample included 
individuals aged 21 years to 64 years who were enrolled in fee-for-service Medicaid for at least 4 
months. Subsamples eligible for each screening test were: Papanicolaou test among 2,136,511 
patients, mammography among 792,470 patients, colonoscopy among 769,729 patients, and fecal 
occult blood test among 753,868 patients. State-specific Medicaid variables included median 
screening test reimbursement, income/financial asset eligibility requirements, physician 
copayments, and frequency of eligibility renewal.
RESULTS—Increases in screening test reimbursement demonstrated mixed associations 
(positive and negative) with the likelihood of receiving screening tests among Medicaid 
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beneficiaries. In contrast, increased reimbursements for office visits were found to be positively 
associated with the odds of receiving all screening tests examined, including colonoscopy (odds 
ratio [OR], 1.07; 95% confidence interval [95% CI], 1.06-1.08), fecal occult blood test (OR, 1.09; 
95% CI, 1.08-1.10), Papanicolaou test (OR, 1.02; 95% CI, 1.02-1.03), and mammography (OR, 
1.02; 95% CI, 1.02-1.03). Effects of other state-specific Medicaid policies varied across the 
screening tests examined.
CONCLUSIONS—Increased reimbursement for office visits was consistently associated with an 
increased likelihood of being screened for cancer, and may be an important policy tool for 
increasing screening among this vulnerable population.
Keywords
Medicaid; access to health care; cancer screening; health insurance reimbursement; health care 
disparities; colonoscopy; mammography; Papanicolaou test
INTRODUCTION
Medicaid, a joint state-federal government health insurance program for certain low-income 
individuals, pays for medical care for a substantial percentage of the US population (an 
estimated 67.7 million individuals in 2010).1 Between 2009 and 2010, Medicaid enrollment 
grew by an estimated 6.2% and is expected to continue to increase over the next several 
years if states chose to expand Medicaid eligibility under the Patient Protection and 
Affordable Care Act.2
Medicaid programs in all states and the District of Columbia (DC) provide coverage for 
breast, cervical, and colorectal cancer screening.3 However, coverage does not guarantee 
receipt of these services. Previous studies have reported that Medicaid beneficiaries were 
less likely to be screened for cancer than individuals with private insurance,4-6 and were 
more likely to present with advanced-stage cancers than patients enrolled in private 
insurance or Medicare.7-11
Within limits set by the federal government, states can establish their own Medicaid 
eligibility requirements and reimbursements.12 Medicaid reimbursements differ substantially 
among states and are usually below Medicare reimbursement levels13; these low 
reimbursements may affect access to cancer screening services. Although findings regarding 
the association between physician reimbursement and the provision of medical care services 
in general are mixed,14-18 low Medicaid reimbursement rates and required office visit 
copayments may decrease access to needed medical care services.7,19-22 Increased Medicaid 
reimbursements are associated with increased access to a usual source of care and the receipt 
of services for both children23,24 and adults.25
State-level variations in Medicaid eligibility policies may also affect health service use, 
including cancer screenings. For example, several Medicaid policies (eg, frequency of 
Medicaid renewal) may affect how long beneficiaries remain enrolled in Medicaid or remain 
with established providers, both of which have been positively correlated with receipt of 
breast and colorectal cancer screening.26,27
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It is important to understand how terms of coverage (ie, eligibility requirements) and 
payments offered to providers affect receipt of preventive care services. The current study 
examined the association between Medicaid reimbursements for cancer screening tests and 
office visits and financial eligibility requirements and the receipt of breast, cervical, and 
colorectal cancer screening.
MATERIALS AND METHODS
Data and Study Population
The current study is a cross-sectional analysis of the 2007 Medicaid Analytic eXtract 
(MAX) claims and enrollment data, which was the most recent year of data available at the 
initiation of this study. The Centers for Medicare and Medicaid Services maintains MAX 
data for all 50 states and DC.28 The study sample included individuals from 46 states and 
DC who were aged 21 years to 64 years, not dually eligible for Medicare, and enrolled in 
fee-for-service Medicaid for at least 4 months. Dual Medicare-Medicaid enrollees and 
enrollees in capitated managed care plans were excluded because their complete service use 
may not be reported in MAX.29 Because beneficiaries with limited Medicaid enrollment 
during the study year would have fewer opportunities to use services, beneficiaries with < 4 
months of enrollment were excluded. However, because many individuals are enrolled in 
Medicaid for relatively short periods of time,30 beneficiaries were not required to have a full 
year of enrollment. Beneficiaries who were pregnant, had ≥ 1 claims with a cancer 
diagnosis, or resided in a long-term care facility were excluded. The Indian Health Service 
provides comprehensive health services to approximately 2 million of the estimated 3.4 
million American Indians/Alaska Natives in the United States.31 Whether the Indian Health 
Service consistently bills Medicaid for cancer screenings is unknown. Therefore, all 
American Indian/Alaska Native Medicaid enrollees were excluded given the likelihood of 
underascertaining receipt of cancer screenings. Because most fee-for-service enrollees in 
Arizona, New Mexico, and Nevada were American Indian and the populations remaining in 
these states after applying this exclusion criterion were atypical compared with the study 
populations of other states, these 3 states were excluded. Maine was also excluded because 
the state did not report physician and outpatient claims in 2007.
From the sample meeting these inclusion criteria, subsamples for each screening test were 
defined based on age and sex. Very few claims for flexible sigmoidoscopy or barium enema 
were included in the Medicaid data, and therefore these procedures were not examined. A 
list of the Current Procedural Terminology (CPT) and International Classification of 
Diseases, Ninth Revision (ICD-9) codes used to identify screening-related claims is shown 
in the online supporting information. For all screening tests except mammography, the same 
codes are used for screening and diagnostic tests, which prevents differentiation between 
cancer screenings and diagnostic procedures.
Independent Variables: State-Specific Reimbursement Rates and Medicaid Policies
For each state, the reimbursement rate for each screening test was defined as the median 
amount paid on outpatient and inpatient claims. Because multiple CPT and ICD-9 codes 
were used for the majority of screening tests examined, the state-specific reimbursement for 
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a test was calculated as the median amount paid in each state for all the identified CPT and 
ICD-9 procedure codes associated with that test. Codes used to determine state-specific 
screening rates and reimbursements are presented in the online supporting information. 
Because there were very few claims that provided separate reimbursements for professional 
and technical components of screening tests, reimbursements included in the current study 
were for the global reimbursement (ie, combined technical and professional component 
reimbursements) for the included screening test.
Because of the significant difference in reimbursement for film versus digital 
mammography, separate reimbursement rates for each type of mammogram were calculated 
as well as for film and digital mammograms billed by facilities (eg, hospitals) and 
nonfacilities (eg, physician's offices). Because screening tests are generally either provided 
or ordered during an office visit, reimbursement for office visits was also considered using 
the state-specific median reimbursement for office visits of moderate severity (CPT code 
99213). State variation in fecal occult blood test (FOBT) reimbursement was minimal 
(range, $1-$7), and therefore state-specific FOBT reimbursement was not included in the 
FOBT regression model.
Medicare's methodology of accounting for regional differences in the costs of medical 
services was used by adjusting reimbursement for mammography and office visits by the 
2007 Medicare Geographic Adjustment Factor and reimbursement for colonoscopy by the 
2007 Hospital Wage Index.
State-specific Medicaid eligibility requirements hypothesized to influence cancer screening 
included income and financial asset thresholds, physician copayments for preventive 
services (required or not required), and frequency of eligibility renewal (12 months or < 12 
months from the initial enrollment date) (see online supporting information). Policy 
information was derived from the Henry J. Kaiser Family Foundation.32-34 Because income 
and financial asset requirements vary by Medicaid eligibility group (parents, blind/disabled, 
or medically needy) within a state, these variables were determined using beneficiaries’ 
eligibility categories. “Less restrictive” income eligibility requirements were defined as 
allowing a maximum income of > 100% of the federal poverty level (FPL) for parents, 75% 
of the FPL for the blind/disabled, and 54% of the FPL for the medically needy. Parents were 
assigned as experiencing a “less restrictive” financial asset policy if they did not have to 
meet an asset test. Because blind/disabled and medically needy populations are subject to 
asset tests in all states, a state's policy was considered “less restrictive” if these populations 
were allowed assets > $2000.
Dependent Variable: Cancer Screening Test Receipt
The outcome of interest was receipt of a colonoscopy, film or digital mammogram, FOBT, 
or Papanicolaou (Pap) test. Select CPT codes and ICD-9 procedure codes were used to 
identify claims for these cancer screening tests (see online supporting information). State-
specific rates for receipt of each screening test are presented in the online supporting 
information. Analyses examine receipt of cancer screenings in 2007 and do not reflect 
adherence to testing intervals recommended in current cancer screening guidelines. 
Furthermore, because screening test rates were based only on 2007 Medicaid claims data 
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(which, for many beneficiaries, involved Medicaid enrollment for less than the full calendar 
year), the screening rates presented in the current study are likely to be lower than those 
from individual surveys or analyses of claims data for individuals enrolled for an entire year.
Statistical Analyses
Multivariable logistic regression was used to measure associations between state-specific 
Medicaid reimbursement and policy variables with receipt of cancer screening tests. To 
account for the clustering of beneficiaries within a state, generalized estimating equations 
assuming an exchangeable working correlation and robust standard errors were used to fit 
logistic regression models. All regressions controlled for age, age squared, sex, race/
ethnicity, urban residence, Medicaid eligibility category, number of inpatient stays, number 
of chronic conditions (conditions and codes listed in the online supporting information), and 
statewide screening rates for the corresponding type of cancer as a partial control for 
unmeasured state-level factors (from the 2008 Behavior Risk Factor Surveillance System; 
2007 estimates were not available).35 To facilitate interpretation, odds ratios were scaled by 
a dollar amount equal to 20% of the national median reimbursement for that screening test 
or office visit.
For mammography, 2 additional covariates were included (the ratio of film to digital 
mammogram claims among Medicare enrollees in the state and the ratio of facility to 
nonfacility mammogram claims in the state's Medicaid claims) to control for state variations 
in the availability of digital versus film mammography and the rates at which different types 
of providers billed for mammograms. An additional 9 states (Delaware, Massachusetts, 
Missouri, Nebraska, New York, Ohio, Utah, West Virginia, and Wyoming) were excluded 
from mammography analyses because these states had no claims for digital mammography 
or lacked both facility and nonfacility claims, thus preventing the creation of these 
independent variables. Maryland was excluded from this analysis because the median 
reimbursement was more than twice that of the next highest state and 6 times the national 
Medicaid reimbursement.
All analyses were weighted by the fee-for-service months an individual was enrolled in 
Medicaid during 2007 and were performed using SAS statistical software (SAS Institute Inc, 
Cary, NC). Study procedures were approved by RTI's Institutional Review Board.
RESULTS
Beneficiary characteristics are summarized in Table 1. The percentage of Medicaid enrollees 
residing in states with less restrictive income requirements ranged from 42% to 57%, and the 
percentage in states with less restrictive asset requirements ranged from 18% to 27%. 
Approximately 80% of beneficiaries resided in states requiring Medicaid renewal every 12 
months and approximately 60% resided in states requiring physician copayments for 
preventive care services. Within the age-appropriate and sex-appropriate samples, 26% of 
patients received a Pap test, 20% received a film or digital mammogram, 6% received a 
colonoscopy, and 4% received a FOBT during the study year.
Halpern et al. Page 5
Cancer. Author manuscript; available in PMC 2016 March 12.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Table 2 summarizes screening test and office visit reimbursements (state-specific rates are 
presented in the online supporting information). National median screening test 
reimbursements ranged from $24 for a Pap test to $271 for colonoscopy; the median office 
visit reimbursement was $37.
Association Between Reimbursement Rates and Cancer Screening
In multivariate regression models, small but significant associations were observed between 
Medicaid reimbursement rates and several screening tests. However, these associations were 
not in a consistent direction. A 20% increase in screening test reimbursement (based on the 
national median reimbursement) was associated with a 1.6% increase in the odds of 
receiving colonoscopy and an 0.8% decrease in the odds of receiving Pap test (Table 3). 
Increased reimbursements for digital mammography at facilities, digital mammography at 
nonfacilities, and film mammography at nonfacilities were associated with 1.2%, 4.0%, and 
1.7% increases, respectively, in the odds of receiving mammography, whereas increased 
reimbursement for film mammography at facilities (the most frequent type of 
mammography claim) was associated with a 5.4% decrease in the odds of receiving 
mammography (Table 4).
In contrast to these mixed results, increased reimbursement for office visits was significantly 
and consistently found to be positively associated with the likelihood of receiving 
colonoscopy, FOBT, Pap test, and mammogram. A 20% increase in office visit 
reimbursement was associated with increases in the odds of screening ranging from 2.2% for 
mammography to 8.7% for FOBT.
Association Between Medicaid Policies and Cancer Screening
The effects of Medicaid policy variables were not uniform across the screening tests 
examined. Beneficiaries in states with less restrictive income eligibility had higher odds of 
receiving Pap tests (P < .001) but lower odds of receiving FOBT tests (P < .001). There was 
no significant relationship noted between income eligibility and receipt of colonoscopy or 
mammography. Less restrictive financial asset policies were found to be negatively 
associated with the odds of receipt of FOBT and positively associated with the odds of 
receipt of all other screening tests (all P < .001); these positive associations ranged from 
7.4% to 12.2% increases in the odds of receiving these screenings. Beneficiaries in states 
requiring Medicaid renewal < 12 months after initial enrollment had higher odds of 
receiving an FOBT (P = .03) or mammogram (P < .001) and lower odds of receiving a Pap 
test (P < .001). The effect size of the association of required renewal at < 12 months on the 
odds of mammography, 11.8%, was substantially larger than other effects on other screening 
tests for this policy factor. Residing in states requiring a copayment for physician services 
was found to be negatively associated with the odds of receiving a colonoscopy, Pap test, or 
mammogram and was positively associated with the odds of receiving a FOBT (all P < .
001).
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DISCUSSION
The current study examined the effects of Medicaid reimbursement rates and eligibility 
requirements on receipt of cancer screening tests among Medicaid enrollees. Increased 
reimbursements for screening tests were associated with generally small and inconsistent 
changes (ie, both positive and negative) in the likelihood of receiving screening tests 
whereas increased office visit reimbursements were associated with a higher likelihood of 
receiving screening for all tests examined. Given the large number of adults enrolled in 
Medicaid, even small increases in screening rates can translate into large numbers of 
additional individuals screened. However, the larger effect sizes and consistently positive 
association observed between office visit reimbursement and receipt of screening tests 
suggest that offices visits may be a more relevant policy tool with which to increase cancer 
screenings compared with test reimbursements.
Less restrictive Medicaid financial asset policies were associated with an increased odds of 
receiving all screening tests except FOBT. However, the relationships between receipt of 
screening and other Medicaid policies examined, including income eligibility, frequency of 
eligibility renewal, and physician copayments, varied across the screening tests.
Increasing reimbursement levels for screening tests may expand the supply of facilities (eg, 
laboratories, imaging facilities) providing services for Medicaid beneficiaries, but increasing 
payments for office visits may increase access to and/or the supply of providers ordering the 
tests. There are substantial barriers for Medicaid enrollees to receive outpatient physician 
care36-38; the results of the current study are consistent with previous studies indicating that 
higher Medicaid reimbursements for office visits are associated with increased receipt of 
health care services, including preventive services.23-25 Medicaid reimbursement rates are 
also associated with physician participation in Medicaid and acceptance of new Medicaid 
patients.20,39-42 The Patient Protection and Affordable Care Act includes provisions 
intended to increase Medicaid provider capacity and improve accessibility for Medicaid 
populations, including the requirement that states increase Medicaid reimbursements for 
certain services provided by primary care providers to Medicare rates in 2013 and 2014. The 
findings of the current study indicate that this requirement may increase the receipt of cancer 
screening tests.
Increased cancer screening among Medicaid enrollees may result in the increased detection 
of cancers at earlier stages.43 Sommers et al recently reported that expanded Medicaid 
eligibility was associated with significantly decreased all-cause mortality.2 As states expand 
Medicaid eligibility, it will be important to track state-specific changes in Medicaid 
enrollment, reimbursement rates, and eligibility requirements, and their impact on cancer 
screening, diagnosis at an early stage, and survival among individuals diagnosed with 
cancer.
The current study includes several limitations. The analyses reflect only the receipt of 
screening tests billed to Medicaid; services rendered without billing or those billed to other 
insurers (eg, Veterans Affairs) were not captured in the data. Because screening test rates 
were based only on 2007 Medicaid claims data (which, for many beneficiaries, involved 
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Medicaid enrollment for less than the full calendar year), the screening rates presented in the 
current study are likely to be lower than those from individual surveys or analyses of claims 
data for individuals enrolled for an entire year. In addition, because the same CPT codes are 
used for all screening and diagnostic tests except for mammography, no differentiation could 
be made between cancer screenings versus diagnostic procedures as a follow-up to 
symptoms or previous abnormal screening results. However, it is likely that a majority of the 
tests were for screening results rather than diagnosis because many more individuals 
undergo screening and because individuals diagnosed with cancer were excluded from the 
current study. Furthermore, although physicians may not submit codes for screening tests 
performed for all patients, and in particular FOBT may not be submitted due to low 
reimbursement, physicians in fee-for-service environments need to submit procedure codes 
to get paid for services provided; therefore, we anticipate that physicians will submit claims 
for screening tests for the majority of patients screened. Because the vast majority of 
screening test claims provided only the global reimbursement for each screening test (ie, 
there were very few claims providing separate reimbursements for professional and 
technical components), we were unable to examine the association between professional and 
technical component reimbursements and rates of screening tests. The current study did not 
include patients in capitated managed care plans; state-level differences in policies regarding 
Medicaid managed care may result in differences between state populations included in the 
study sample.
A recently published study reported that breast, cervical, and colorectal cancer screenings 
are not covered in all states for Medicaid beneficiaries.44 However, a report for the Kaiser 
Family Foundation and other information have indicated that these cancer screenings are 
covered in all states and DC.3,45,46 Furthermore, substantial numbers of claims and 
reimbursements were identified for all these screening tests in all states included in the 
current study (see online supporting information). Therefore, we believe that these cancer 
screenings were covered for Medicaid beneficiaries in all included states during the study 
period. The current study is a cross-sectional analysis, and unmeasured state-level factors 
may affect results. Statewide screening rates for the corresponding type of cancer were 
included as a partial control for unmeasured state-level factors. Because previous work has 
indicated limited changes in Medicaid cancer screening reimbursements across years,47 this 
cross-sectional comparison is likely to demonstrate more policy variation than a longitudinal 
study of state reimbursement rates over time. Multiple previous studies have examined the 
impact of a variety of disparities on cancer screening using cross-sectional comparisons.48-51 
Finally, adherence to 2007 recommendations for cancer screenings with multiyear intervals 
could not be examined.
As Medicaid programs continue to evolve, these findings may assist policy makers in 
examining ways in which reimbursements for cancer screening tests and office visits and 
eligibility policies could be used to address barriers to access to care and improve the uptake 
of cancer screening services.
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TABLE 1
Select Sociodemographic Characteristics and Cancer Screening Rates Within the Study Sample That Is Age-/
Sex-Eligible for the Screening Test
Characteristic, Column Mean and Percentagea Females Aged 21-64 Years N=2,136,511
Females Aged 40-64 
Years N=792,470
Males and Females Aged 
50-64 Years N = 769,729
Type of Screening Cervical Cancer Breast Cancer Colorectal Cancer
Mean age, y 40 50 56
Female, % 100.0 100.0 59.5
Race/ethnicity, %
    White 51.7 48.6 49.9
    Black 27.6 27.7 25.5
    Hispanic 10.5 9.9 9.8
    Other race 10.2 13.9 14.8
No. of chronic conditions, %
    1 22.9 26.7 26.1
    ≥2 24.1 40.4 46.2
Residence, %
    Large metropolitan area 36.3 36.7 43.7
    Small metropolitan area 35.0 34.2 30.4
    Nonmetropolitan area adjacent to metropolitan 
area
17.7 18.3 15.8
    Nonmetropolitan area not adjacent to metropolitan 
area
11.1 10.8 10.1
Medicaid eligibility category, %
    Parent 43.7 21.7 9.3
    Blind/disabled 47.3 71.2 86.5
    Medically needy 9.0 7.1 4.2
    Less restrictive income eligibility requirement, % 41.9 45.0 56.8
    Less restrictive financial asset requirements, % 27.0 18.3 23.1
    Frequency of Medicaid renewal <12 mo, % 20.7 21.4 19.2
    Physician copayment in the state of residence, % 59.6 66.9 57.9
Receipt of cancer screening test, %
    Colonoscopy – – 5.7
    FOBTb – – 4.4
    Digital or film mammography – 20.3 –
    Pap test 25.8 – –
Abbreviations: FOBT, fecal occult blood test; Pap, Papanicolaou.
a
Percentages were weighted by the number of months an individual was enrolled in fee-for-service Medicaid.
b
The numbers of Medicaid enrollees eligible for FOBT and for colonoscopy differ because the colonoscopy population (769,729 individuals) 
excluded enrollees who received an FOBT earlier in the observation period and the FOBT population (753,868) excluded enrollees who underwent 
a colonoscopy earlier in the observation period.
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TABLE 2
Median State Medicaid Reimbursement Rates for Cancer Screening Tests and Office Visitsa
Reimbursement Range, $b
National Median, $ Minimum Amount (State) Maximum Amount (State)
Colonoscopy 270.94 83.94 (NY) 598.20 (AK)
Digital mammography, facility 49.16 16.84 (FL) 136.31 (ND)
Digital mammography, nonfacility 84.95 25.03 (LA) 209.25 (VT)
Film mammography, facility 30.51 16.53 (FL) 64.34 (SC)
Film mammography, nonfacility 53.75 28.00 (NH) 79.11 (VA)
Pap test 24.00 4.00 (IL) 36.00 (NC)
Office visit 36.85 20.67 (RI) 79.62 (AK)
Abbreviation: Pap, Papanicolaou.
a
Fecal occult blood test reimbursement rates were not included. Because state variations in reimbursement were minimal, reimbursement for fecal 
occult blood tests was not examined in regression models.
bStates excluded from the regression analysis for a particular screening test were excluded from the determination of minimum and maximum 
reimbursement rates.
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TABLE 3
Adjusted ORs (95% CI) for Receipt of Colonoscopy, FOBT, and Pap Test
Colonoscopy N = 
769,729
P FOBT N = 753,868 P Pap Test N=2,136,511 P
Reimbursement variablesa
    State median reimbursement for 
cancer screening test
1.016 (1.011-1.027) <.001 NA 0.992 (0.989-0.995) <.001
    State median reimbursement for an 
office visit
1.069 (1.060-1.078) <.001 1.087 (1.077-1.097) <.001 1.023 (1.020-1.026) <.001
Sociodemographic and other variables
    Ageb 1.053 (0.975-1.137) .19 1.177 (1.077-1.287) <.001 0.982 (0.980-0.984) <.001
Sex
    Female Reference Reference Reference
    Male 0.829 (0.812-0.847) <.001 0.666 (0.649-0.683) <.001 NA
Race/ethnicity
    White Reference Reference Reference
    Black 0.867 (0.846-0.890) <.001 0.834 (0.809-0.859) <.001 1.078 (1.070-1.087) <.001
    Hispanic 1.043 (1.006-1.081) .02 1.226 (1.178-1.276) <.001 1.163 (1.149-1.176) <.001
    Other 0.957 (0.928-0.986) .01 1.256 (1.216-1.296) <.001 1.039 (1.027-1.051) <.001
No. of chronic conditions
    0 Reference Reference Reference
    1 2.193 (2.120-2.268) <.001 2.049 (1.972-2.128) <.001 1.554 (1.541-1.567) <.001
    ≥2 2.956 (2.864-3.051) <.001 2.537 (2.449-2.628) <.001 1.731 (1.714-1.748) <.001
Residence
    Large metropolitan area Reference Reference Reference
    Small metropolitan area 1.092 (1.064-1.121) <.001 1.066 (1.035-1.097) <.001 1.123 (1.114-1.133) <.001
    Non metropolitan area adjacent to 
metropolitan area
1.074 (1.040-1.109) <.001 0.997 (0.962-1.034) .88 1.172 (1.160-1.184) <.001
    Nonmetropolitan area not adjacent to 
metropolitan area
1.021 (0.983-1.061) .28 0.878 (0.839-0.918) <.001 1.181 (1.167-1.196) <.001
    No. of inpatient stays 1.084 (1.074-1.093) <.001 1.069 (1.060-1.079) <.001 0.905 (0.900-0.910) <.001
Medicaid eligibility category
    Parents Reference Reference Reference
    Blind/disabled 0.984 (0.947-1.022) .39 1.191 (1.138-1.246) <.001 0.745 (0.738-0.751) <.001
    Medically needy 1.073 (1.009-1.142) .03 0.965 (0.892-1.044) .37 0.930 (0.918-0.943) <.001
    State BRFSS cancer screening rate 1.021 (1.018-1.024) <.001 1.043 (1.040-1.046) <.001 1.055 (1.053-1.057) <.001
State Medicaid variables
    Income eligibility
    More restrictive Reference Reference Reference
    Less restrictive 0.995 (0.971-1.019) .66 0.857 (0.835-0.880) <.001 1.056 (1.047-1.066) <.001
Financial assets
    More restrictive Reference Reference Reference
    Less restrictive 1.074 (1.045-1.103) <.001 0.914 (0.885-0.943) <.001 1.122 (1.114-1.131) <.001
Frequency of Medicaid renewal
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Colonoscopy N = 
769,729
P FOBT N = 753,868 P Pap Test N=2,136,511 P
    12 mo Reference Reference Reference
<12 mo 1.016 (0.988-1.044) .27 1.034 (1.003-1.067) .03 0.981 (0.972-0.990) <.001
Requires physician copayment
    No Reference Reference Reference
    Yes 0.939 (0.918-0.959) <.001 1.142 (1.114-1.170) <.001 0.944 (0.937-0.951) <.001
Abbreviations: 95% CI, 95% confidence interval; BRFSS, Behavioral Risk Factor Surveillance System; FOBT, fecal occult blood test; NA, not 
applicable; OR, odds ratio; Pap, Papanicolaou.
aORs for the reimbursement variables were scaled by the dollar amount equal to 20% of the national median reimbursement for that screening test/
office visit.
bAge-squared (ie, age times age) was also included in all regression models (results not shown).
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TABLE 4
Adjusted ORs (95% CI) for Receipt of Mammographya
Film and Digital Mammography N=792,470 P
Reimbursement variablesb
    State median reimbursement for digital mammography, facility 1.012 (1.007-1.016) <.001
    State median reimbursement for digital mammography, nonfacility 1.040 (1.035-1.045) <.001
    State median reimbursement for film mammography, facility 0.946 (0.942-0.951) <.001
    State median reimbursement for film mammography, nonfacility 1.017 (1.011-1.023) <.001
    State median reimbursement for an office visit 1.022 (1.016-1.028) <.001
Sociodemographic and other variables
    Agec 1.196 (1.179-1.213) <.001
Race/ethnicity
    White Reference
    Black 0.964 (0.950-0.978) <.001
    Hispanic 1.306 (1.280-1.333) <.001
    Other race 1.084 (1.065-1.103) <.001
No. of chronic conditions
    0 Reference
    1 1.901 (1.870-1.932) <.001
    ≥2 2.377 (2.339-2.415) <.001
Residence
    Large metropolitan area Reference
    Small metropolitan area 1.234 (1.216-1.253) <.001
    Nonmetropolitan area adjacent to metropolitan area 1.272 (1.249-1.296) <.001
    Nonmetropolitan area not adjacent to metropolitan area 1.276 (1.247-1.305) <.001
    No. of inpatient stays 0.807 (0.799-0.814) <.001
Medicaid eligibility category
Adult Reference
    Blind/disabled 0.932 (0.915-0.949) <.001
    Medically needy 0.864 (0.839-0.891) <.001
    State BRFSS mammogram screening rate 1.033 (1.030-1.036) <.001
    State-level ratio of film to digital mammography claims in Medicare 0.855 (0.827-0.883) <.001
    State-level ratio of facility to nonfacility mammogram claims 1.004 (1.003-1.004) <.001
    State Medicaid variables
Income eligibility
    More restrictive Reference
    Less restrictive 1.013 (0.996-1.031) .14
Asset test
    More restrictive Reference
    Less restrictive 1.074 (1.055-1.093) <.001
Medicaid redetermination
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Film and Digital Mammography N=792,470 P
    12 mo Reference
    <12 mo 1.118 (1.098-1.139) <.001
Requires physician copayment
    No Reference
    Yes 0.909 (0.893-0.925) <.001
Abbreviations: 95% CI, 95% confidence interval; BRFSS, Behavioral Risk Factor Surveillance System; OR, odds ratio.
aNine states (Delaware, Massachusetts, Missouri, Nebraska, New York, Ohio, Utah, West Virginia, and Wyoming) were excluded from the 
regression analysis because a reimbursement variable could not be created because the state had no claims for digital mammography or no claims 
associated with a facility or a nonfacility. Maryland was also excluded because mammogram reimbursement was very high.
bORs for the reimbursement variables were scaled by the dollar amount equal to 20% of the national median reimbursement for facility and 
nonfacility film/digital mammograms and office visits.
cAge-squared (ie, age times age) was also included in all regression models (results not shown).
Cancer. Author manuscript; available in PMC 2016 March 12.
